{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:56:08Z","timestamp":1790834168055,"version":"4.1.0"},"reference-count":68,"publisher":"Lavoisier","issue":"3","license":[{"start":{"date-parts":[[2017,4,17]],"date-time":"2017-04-17T00:00:00Z","timestamp":1492387200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bull. Soc. Pathol. Exot."],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s13149-017-0556-z","type":"journal-article","created":{"date-parts":[[2017,4,17]],"date-time":"2017-04-17T08:07:06Z","timestamp":1492416426000},"page":"198-206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Place de la primaquine dans la lutte contre le paludisme en Afrique francophone","Role of primaquine in malaria control and elimination in French-speaking Africa"],"prefix":"10.3166","volume":"110","author":[{"given":"S.","family":"Briolant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Pradines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. K.","family":"Basco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1762","published-online":{"date-parts":[[2017,4,17]]},"reference":[{"key":"556_CR1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/1756-3305-6-278","volume":"6","author":"SM Abay","year":"2013","unstructured":"Abay SM (2013) Blocking malaria transmission to anopheles mosquitoes using artemisinin derivatives and primaquine: a systematic review and meta-analysis. Parasit Vectors 6:278","journal-title":"Parasit Vectors"},{"key":"556_CR2","doi-asserted-by":"crossref","first-page":"0125796","DOI":"10.1371\/journal.pone.0125796","volume":"10","author":"D Adu-Gyasi","year":"2015","unstructured":"Adu-Gyasi D, Asante KP, Newton S, et al (2015) Evaluation of the diagnostic accuracy of CareStart\u2122 G6PD deficiency rapid diagnostic test (RDT) in a malaria endemic area in Ghana, Africa. PLoS One 10:e0125796","journal-title":"PLoS One"},{"key":"556_CR3","first-page":"391","volume":"46","author":"J Arnold","year":"1955","unstructured":"Arnold J, Alving AS, Hockwald RS, et al (1955) The antimalarial action of primaquine against the blood and tissue stages of falciparum malaria (Panama, P-F-6 strain). J Lab Clin Med 46:391\u20137","journal-title":"J Lab Clin Med"},{"key":"556_CR4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/1475-2875-13-418","volume":"13","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Recht J, White NJ (2014) Primaquine: the risks and the benefits. Malar J 13:418","journal-title":"Malar J"},{"key":"556_CR5","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/infdis\/171.6.1678","volume":"171","author":"JK Baird","year":"1995","unstructured":"Baird JK, Basri H, Subianto B, et al (1995) Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis 171:1678\u201382","journal-title":"J Infect Dis"},{"key":"556_CR6","doi-asserted-by":"crossref","unstructured":"Baird JK, Rieckmann KH (2003) Can primaquine therapy for vivax malaria be improved? Trends Parasitol 19:115\u201320","DOI":"10.1016\/S1471-4922(03)00005-9"},{"key":"556_CR7","doi-asserted-by":"crossref","first-page":"659","DOI":"10.4269\/ajtmh.2002.66.659","volume":"66","author":"JK Baird","year":"2002","unstructured":"Baird JK, Wiady I, Sutanihardja A, et al (2002) Therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia. Am J Trop Med Hyg 66:659\u201360","journal-title":"Am J Trop Med Hyg"},{"key":"556_CR8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/00034983.1999.11813408","volume":"93","author":"LK Basco","year":"1999","unstructured":"Basco LK, Bickii J, Ringwald P (1999) In-vitro activity of primaquine against the asexual blood stages of Plasmodium falciparum. Ann Trop Med Parasitol 93:179\u201382","journal-title":"Ann Trop Med Parasitol"},{"key":"556_CR9","first-page":"137","volume-title":"M\u00e9mento th\u00e9rapeutique du paludisme en Afrique","author":"O Bouchaud","year":"2008","unstructured":"Bouchaud O, Doumbo O, Gaye O, et al (2008) M\u00e9mento th\u00e9rapeutique du paludisme en Afrique. Doin \u00c9ditions, 137 p"},{"key":"556_CR10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(08)60073-2","volume":"371","author":"MD Cappellini","year":"2008","unstructured":"Cappellini MD, Fiorelli G (2008) Glucose-6-phosphate dehydrogenase deficiency. Lancet 371:64\u201374","journal-title":"Lancet"},{"key":"556_CR11","first-page":"8","volume-title":"Treatment of malaria: guidelines for clinicians","author":"Centers for Disease ControlPrevention","year":"2015","unstructured":"Centers for Disease Control and Prevention (2015) Treatment of malaria: guidelines for clinicians (United States), 8 p"},{"key":"556_CR12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.actatropica.2015.08.008","volume":"152","author":"A Cheoymang","year":"2015","unstructured":"Cheoymang A, Ruenweerayut R, Muhamad P, et al (2015) Patients\u2019 adherence and clinical effectiveness of a 14-day course of primaquine when given with a 3-day chloroquine in patients with Plasmodium vivax at the Thai-Myanmar border. Acta Trop 152:151\u20136","journal-title":"Acta Trop"},{"key":"556_CR13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4269\/ajtmh.1996.55.243","volume":"55","author":"WE Collins","year":"1996","unstructured":"Collins WE, Jeffery GM (1996) Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg 55:243\u20139","journal-title":"Am J Trop Med Hyg"},{"key":"556_CR14","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1371\/journal.pone.0005318","volume":"4","author":"B Coulibaly","year":"2009","unstructured":"Coulibaly B, Zoungrana A, Mockenhaupt FP, et al (2009) Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial. PLoS One 4:e5318","journal-title":"PLoS One"},{"key":"556_CR15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1517\/13543784.16.5.705","volume":"16","author":"M Crockett","year":"2007","unstructured":"Crockett M, Kain KC (2007) Tafenoquine: a promising new antimalarial agent. Expert Opin Investig Drugs 16:705\u201315","journal-title":"Expert Opin Investig Drugs"},{"key":"556_CR16","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1086\/644510","volume":"200","author":"R Culleton","year":"2009","unstructured":"Culleton R, Ndounga M, Zeyrek FY, et al (2009) Evidence for the transmission of Plasmodium vivax in the Republic of the Congo, West Central Africa. J Infect Dis 200:1465\u20139","journal-title":"J Infect Dis"},{"key":"556_CR17","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/1475-2875-11-360","volume":"11","author":"AC Eziefula","year":"2012","unstructured":"Eziefula AC, Gosling R, Hwang J, et al (2012) Rationale for short course primaquine in Africa to interrupt malaria transmission. Malar J 11:360","journal-title":"Malar J"},{"key":"556_CR18","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0035-9203(98)90900-2","volume":"92","author":"FB Faye","year":"1998","unstructured":"Faye FB, Konat\u00e9 L, Rogier C, Trape JF (1998) Plasmodium ovale in a highly malaria endemic area of Senegal. Trans R Soc Trop Med Hyg 92:522\u20135","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"556_CR19","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1086\/342395","volume":"186","author":"FB Faye","year":"2002","unstructured":"Faye FB, Spiegel A, Tall A, et al (2002) Diagnostic criteria and risk factors for Plasmodium ovale malaria. J Infect Dis 186:690\u20135","journal-title":"J Infect Dis"},{"key":"556_CR20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/1475-2875-10-351","volume":"10","author":"D Fernando","year":"2011","unstructured":"Fernando D, Rodrigo C, Rajapakse S (2011) Primaquine in vivax malaria: an update and review on management issues. Malar J 10:351","journal-title":"Malar J"},{"key":"556_CR21","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1475-2875-13-170","volume":"13","author":"J Fru-Cho","year":"2014","unstructured":"Fru-Cho J, Bumah VV, Safeukui I, et al (2014) Molecular typing reveals substantial Plasmodium vivax infection in asymptomatic adults in a rural area of Cameroon. Malar J 13:170","journal-title":"Malar J"},{"key":"556_CR22","first-page":"CD004389","volume":"1","author":"GNL Galappaththy","year":"2007","unstructured":"Galappaththy GNL, Omari AAA, Tharyan P (2007) Primaquine for preventing relapses in people with Plasmodium vivax malaria. Cochrane Database Syst Rev 1):CD004389","journal-title":"Cochrane Database Syst Rev"},{"key":"556_CR23","first-page":"CD004389","volume":"10","author":"GNL Galappaththy","year":"2013","unstructured":"Galappaththy GNL, Tharyan P, Kirubakaran R (2013) Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. Cochrane Database Syst Rev 10):CD004389","journal-title":"Cochrane Database Syst Rev"},{"key":"556_CR24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/s12936-015-0938-2","volume":"14","author":"L Gonzalez-Ceron","year":"2015","unstructured":"Gonzalez-Ceron L, Rodriguez MH, Sandoval MA, et al (2015) Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico. Malar J 14: 426","journal-title":"Malar J"},{"key":"556_CR25","first-page":"CD008152","volume":"6","author":"PM Graves","year":"2014","unstructured":"Graves PM, Gelband H, Garner P (2014) Primaquine or other 8- aminoquinoline for reducing Plasmodium falciparum transmission. Cochrane Database Syst Rev 6):CD008152","journal-title":"Cochrane Database Syst Rev"},{"key":"556_CR26","first-page":"363","volume":"21\u201322","author":"Haut Conseil de la sant\u00e9 publique","year":"2015","unstructured":"Haut Conseil de la sant\u00e9 publique (2015) Recommandations sanitaires pour les voyageurs, 2015 (\u00e0 l\u2019attention des professionnels de sant\u00e9). Bull Epidemiol Hebd 21\u201322:363\u2013421","journal-title":"Bull Epidemiol Hebd"},{"key":"556_CR27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1517\/13543784.2015.1000483","volume":"24","author":"J Held","year":"2015","unstructured":"Held J, Jeyaraj S, Kreidenweiss A (2015) Antimalarial compounds in phase II clinical development. Expert Opin Investig Drugs 24:363\u201382","journal-title":"Expert Opin Investig Drugs"},{"key":"556_CR28","doi-asserted-by":"crossref","first-page":"402","DOI":"10.4269\/ajtmh.2006.75.402","volume":"75","author":"DR Hill","year":"2006","unstructured":"Hill DR, Baird JK, Parise ME, et al (2006) Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 75:402\u201315","journal-title":"Am J Trop Med Hyg"},{"key":"556_CR29","doi-asserted-by":"crossref","first-page":"e0004222","DOI":"10.1371\/journal.pntd.0004222","volume":"9","author":"RE Howes","year":"2015","unstructured":"Howes RE, Reiner RC, Battle KE, et al (2015) Plasmodium vivax transmission in Africa. PLoS Negl Trop Dis 9: e0004222","journal-title":"PLoS Negl Trop Dis"},{"key":"556_CR30","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/1475-2875-11-280","volume":"11","author":"GK John","year":"2012","unstructured":"John GK, Douglas NM, von Seidlein L, et al (2012) Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J 11:280","journal-title":"Malar J"},{"key":"556_CR31","doi-asserted-by":"crossref","first-page":"28357","DOI":"10.1371\/journal.pone.0028357","volume":"6","author":"S Kim","year":"2011","unstructured":"Kim S, Nguon C, Guillard B, et al (2011) Performance of the CareStart\u2122 G6PD deficiency screening test, a point-of-care diagnostic for primaquine therapy screening. PLoS One 6:e28357","journal-title":"PLoS One"},{"key":"556_CR32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1475-2875-13-51","volume":"13","author":"A Kondrashin","year":"2014","unstructured":"Kondrashin A, Baranova AM, Ashley EA, et al (2014) Mass primaquine treatment to eliminate vivax malaria: lessons from the past. Malar J 13:51","journal-title":"Malar J"},{"key":"556_CR33","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/BF00928413","volume":"77","author":"HN Lanners","year":"1991","unstructured":"Lanners HN (1991) Effect of the 8-aminoquinoline primaquine on culture-derived gametocytes of the malaria parasite Plasmodium falciparum. Parasitol Res 77:474\u201381","journal-title":"Parasitol Res"},{"key":"556_CR34","doi-asserted-by":"crossref","first-page":"103262","DOI":"10.1371\/journal.pone.0103262","volume":"9","author":"HGN Mbenda","year":"2014","unstructured":"Mbenda HGN, Das A (2014) Molecular evidence of Plasmodium vivax mono and mixed malaria parasite infections in Duffy-negative native Cameroonians. PLoS One 9:e103262","journal-title":"PLoS One"},{"key":"556_CR35","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1073\/pnas.0912496107","volume":"107","author":"D M\u00e9nard","year":"2010","unstructured":"M\u00e9nard D, Barnadas C, Bouchier C, et al (2010) Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc Natl Acad Sci USA 107:5967\u201371","journal-title":"Proc Natl Acad Sci USA"},{"key":"556_CR36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.tracli.2010.06.005","volume":"17","author":"O Mercereau-Puijalon","year":"2010","unstructured":"Mercereau-Puijalon O, M\u00e9nard D (2010) Plasmodium vivax and the Duffy antigen: a paradigm revisited. Transfus Clin Biol 17:176\u201383","journal-title":"Transfus Clin Biol"},{"key":"556_CR37","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12936-015-0607-5","volume":"14","author":"K Mint Lekweiry","year":"2015","unstructured":"Mint Lekweiry K, Ould Ahmedou Salem MS, Basco LK, et al (2015) Malaria in Mauritania: retrospective and prospective overview. Malar J 14:100","journal-title":"Malar J"},{"key":"556_CR38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12936-015-0808-y","volume":"14","author":"M Niang","year":"2015","unstructured":"Niang M, Thiam LG, Sow A, et al (2015) A molecular survey of acute febrile illnesses reveals Plasmodium vivax infections in Kedougou, south-eastern Senegal. Malar J 14:281","journal-title":"Malar J"},{"key":"556_CR39","first-page":"601","volume":"67","author":"OMS","year":"1989","unstructured":"OMS (1989) Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Organ 67:601\u201311","journal-title":"Bull World Health Organ"},{"key":"556_CR40","unstructured":"OMS (1997) Management of uncomplicated malaria and the use of antimalarial drugs for the protection of travellers. Report of an informal consultation. Gen\u00e8ve, 18\u201321 September 1995, WHO\/MAL\/96.1075 Rev. 1, 98 p"},{"key":"556_CR41","unstructured":"OMS (2001) The use of antimalarial drugs. Report of an informal consultation. Gen\u00e8ve. WHO\/CDS\/RBM\/2001.33, 144 p"},{"key":"556_CR42","unstructured":"OMS (2010) Guidelines for the treatment of malaria. Second edition. World Health Organization, Geneva"},{"key":"556_CR43","first-page":"19","volume-title":"The safety and effectiveness of single dose primaquine as a P. falciparum gametocytocide","author":"OMS","year":"2012","unstructured":"OMS (2012) The safety and effectiveness of single dose primaquine as a P. falciparum gametocytocide. Bangkok, Thailand, 19 p"},{"key":"556_CR44","first-page":"242","volume-title":"World malaria report 2014","author":"OMS","year":"2014","unstructured":"OMS (2014) World malaria report 2014. World Health Organization, Geneva, 242 p"},{"key":"556_CR45","unstructured":"OMS (2014) Voyages internationaux et sant\u00e9. Mises \u00e0 jour 2014 (en ligne)"},{"key":"556_CR46","first-page":"317","volume-title":"Guidelines for the treatment of malaria","author":"OMS","year":"2015","unstructured":"OMS (2015) Guidelines for the treatment of malaria. 3rd edition. World Health Organization, Geneva, 317 p"},{"key":"556_CR47","doi-asserted-by":"crossref","first-page":"537","DOI":"10.4269\/ajtmh.14-0243","volume":"92","author":"MS Ould Ahmedou Salem","year":"2015","unstructured":"Ould Ahmedou Salem MS, Mint Lekweiry K, Mint Deida J, et al (2015) Increasing prevalence of Plasmodium vivax among febrile patients in Nouakchott, Mauritania. Am J Trop Med Hyg 92:537\u201340","journal-title":"Am J Trop Med Hyg"},{"key":"556_CR48","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1128\/AAC.01466-10","volume":"55","author":"A Pascual","year":"2011","unstructured":"Pascual A, Henry M, Briolant S, et al (2011) In vitro activity of proveblue (methylene blue) on Plasmodium falciparum strains resistant to standard antimalarial drugs. Antimicrob Agents Chemother 55:2472\u20134","journal-title":"Antimicrob Agents Chemother"},{"key":"556_CR49","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1128\/AAC.00777-06","volume":"50","author":"B Pradines","year":"2006","unstructured":"Pradines B, Mamfoumbi MM, Tall A, et al (2006) In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti. Antimicrob Agents Chemother 50:3225\u20136","journal-title":"Antimicrob Agents Chemother"},{"key":"556_CR50","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(96)91488-9","volume":"347","author":"RN Price","year":"1996","unstructured":"Price RN, Nosten F, Luxemburger C, et al (1996) Effects of artemisinin derivatives on malaria transmissibility. Lancet 347:1654\u20138","journal-title":"Lancet"},{"key":"556_CR51","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/infdis\/169.4.932","volume":"169","author":"S Pukrittayakamee","year":"1994","unstructured":"Pukrittayakamee S, Vanijanonta S, Chantra A, et al (1994) Blood-stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J Infect Dis 169:932\u20135","journal-title":"J Infect Dis"},{"key":"556_CR52","first-page":"CD010458","volume":"4","author":"S Rajapakse","year":"2015","unstructured":"Rajapakse S, Rodrigo C, Fernando SD (2015) Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. Cochrane Database Syst Rev 4):CD010458","journal-title":"Cochrane Database Syst Rev"},{"key":"556_CR53","first-page":"225","volume-title":"Safety of 8-aminoquinoline antimalarial medicines","author":"J Recht","year":"2014","unstructured":"Recht J, Ashley E, White N (2014) Safety of 8-aminoquinoline antimalarial medicines. World Health Organization, Geneva, 225 p"},{"key":"556_CR54","first-page":"349","volume":"95","author":"PA Reeve","year":"1992","unstructured":"Reeve PA, Toaliu H, Kaneko A, et al (1992) Acute intravascular haemolysis in Vanuatu following a single dose of primaquine in individuals with glucose-6-phosphate dehydrogenase deficiency. J Trop Med Hyg 95:349\u201351","journal-title":"J Trop Med Hyg"},{"key":"556_CR55","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00436-010-2071-z","volume":"107","author":"J Richter","year":"2010","unstructured":"Richter J, Franken G, Mehlhorn H, et al (2010) What is the evidence for the existence of Plasmodium ovale hypnozoites? Parasitol Res 107:1285\u201390","journal-title":"Parasitol Res"},{"key":"556_CR56","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12936-015-0824-y","volume":"14","author":"K Rishikesh","year":"2015","unstructured":"Rishikesh K, Kamath A, Hande MH, et al (2015) Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India. Malar J 14:310","journal-title":"Malar J"},{"key":"556_CR57","doi-asserted-by":"crossref","first-page":"1001891","DOI":"10.1371\/journal.pmed.1001891","volume":"12","author":"LJ Robinson","year":"2015","unstructured":"Robinson LJ, Wampfler R, Betuela I, et al (2015) Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model. PLoS Med 12:e1001891","journal-title":"PLoS Med"},{"key":"556_CR58","first-page":"11","volume-title":"Renseignements th\u00e9rapeutiques","author":"Sanofi-Aventis","year":"2015","unstructured":"Sanofi-Aventis (2015) Renseignements th\u00e9rapeutiques. Primaquine, 11 p"},{"key":"556_CR59","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1371\/journal.pone.0001023","volume":"2","author":"S Shekalaghe","year":"2007","unstructured":"Shekalaghe S, Drakeley C, Gosling R, et al (2007) Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. PLoS One 2:e1023","journal-title":"PLoS One"},{"key":"556_CR60","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/jac\/dku326","volume":"70","author":"R Suwanarusk","year":"2015","unstructured":"Suwanarusk R, Russell B, Ong A, et al (2015) Methylene blue inhibits the asexual development of vivax malaria parasites from a region of increasing chloroquine resistance. J Antimicrob Chemother 70:124\u20139","journal-title":"J Antimicrob Chemother"},{"key":"556_CR61","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4269\/ajtmh.2010.09-0416","volume":"82","author":"KE Tinley","year":"2010","unstructured":"Tinley KE, Loughlin AM, Jepson A, Barnett ED (2010) Evaluation of a rapid qualitative enzyme chromatographic test for glucose-6-phosphate dehydrogenase deficiency. Am J Trop Med Hyg 82:210\u20134","journal-title":"Am J Trop Med Hyg"},{"key":"556_CR62","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0166-6851(93)90088-F","volume":"58","author":"AB Vaidya","year":"1993","unstructured":"Vaidya AB, Lashgari MS, Pologe LG, Morrisey J (1993) Structural features of Plasmodium cytochrome b that may underlie susceptibility to 8-aminoquinolines and hydroxynaphthoquinones. Mol Biochem Parasitol 58:33\u201342","journal-title":"Mol Biochem Parasitol"},{"key":"556_CR63","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ejmech.2008.08.011","volume":"44","author":"N Vale","year":"2009","unstructured":"Vale N, Moreira R, Gomes P (2009) Primaquine revisited six decades after its discovery. Eur J Med Chem 44:937\u201353","journal-title":"Eur J Med Chem"},{"key":"556_CR64","first-page":"1383","volume-title":"Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics","author":"JM Vinetz","year":"2011","unstructured":"Vinetz JM, Clain J, Bounkeua V, et al (2011) Chemotherapy of malaria. In: Brunton LL, Chabner BA, Knollmann BC (eds) Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics. Twelfth edition, McGraw-Hill Companies, Inc., New York, pp 1383\u2013418"},{"key":"556_CR65","first-page":"164","volume-title":"Primaquine: pharmacokinetics, metabolism, toxicity and activity: proceedings of a meeting of the scientific working group on the chemotherapy of malaria, UNDP\/World Bank\/WHO Special Programme for Research and Training in Tropical Diseases","year":"1987","unstructured":"Wernsdorfer WH, Trigg PI (eds) (1987) Primaquine: pharmacokinetics, metabolism, toxicity and activity: proceedings of a meeting of the scientific working group on the chemotherapy of malaria, UNDP\/World Bank\/WHO Special Programme for Research and Training in Tropical Diseases, held in Geneva, Switzerland, 27\u201328 February 1984, 164 p"},{"key":"556_CR66","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1186\/1475-2875-13-483","volume":"13","author":"NJ White","year":"2014","unstructured":"White NJ, Ashley EA, Recht J, et al (2014) Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria. Malar J 13:483","journal-title":"Malar J"},{"key":"556_CR67","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/1475-2875-11-418","volume":"11","author":"NJ White","year":"2012","unstructured":"White NJ, Qiao LG, Qi G, Luzzatto L (2012) Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar J 11:418","journal-title":"Malar J"},{"key":"556_CR68","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/1475-2875-10-336","volume":"10","author":"N Wurtz","year":"2011","unstructured":"Wurtz N, Mint Lekweiry K, Bogreau H, et al (2011) Vivax malaria in Mauritania includes infection of a Duffy-negative individual. Malar J 10:336","journal-title":"Malar J"}],"container-title":["Bulletin de la Soci\u00e9t\u00e9 de pathologie exotique"],"original-title":[],"language":"fr","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13149-017-0556-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13149-017-0556-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13149-017-0556-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T23:37:09Z","timestamp":1569022629000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13149-017-0556-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,17]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["556"],"URL":"https:\/\/doi.org\/10.1007\/s13149-017-0556-z","relation":{},"ISSN":["0037-9085","1961-9049"],"issn-type":[{"value":"0037-9085","type":"print"},{"value":"1961-9049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,17]]}}}